International, multicenter, randomized, parallel group, double-blind study, in patients with acute symptomatic deep vein thrombosis of the lower limbs, demonstrating the bioequipotency at steady state of equimolar doses of SSR126517E (3.0 mg) once a week and SR34006 (2.5 mg) once a week, documenting the safety and efficacy of both compounds during a 6-month treatment, and demonstrating the neutralizing effect of SSR29261 on the SSR126517E-induced anti-Xa activity Objetivo principal de la evaluación de bioequipotencia: Demostrar la bioequipotencia de idraparinux biotinilato (SSR126517E) e idraparinux (SR34006) en fase meseta, en pacientes con TVP sintomática a...

• Country None
• organs None
• Specialty None

an eight-week, multicenter, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of one fixed 100 mg dose of Saredutant in patients with Major Depressive Disorder To evaluate the efficacy of a 100 mg fixed dose of saredutant compared to placebo in patients with major depressive disorder

• Country None
• organs None
• Specialty None

A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter study evaluating the efficacy and safety of four doses of SR147778 in obese patients To assess the effect of SR147778 on weight loss over a period of 24 weeks when prescribed with a hypocaloric diet in obese patients.

• Country None
• organs None
• Specialty None

Placebo controlled double blind dose ranging study of the efficacy and safety of SSR149744C 50, 100, 200, or 300 mg OD, with amiodarone as calibrator for the maintenance of sinus rhythm in patients with recent atrial fibrillation/flutter To evaluate the efficacy of SSR149744C and select a dose to be further investigated in the maintenance of sinus rhythm after electrical, pharmacological or spontaneous conversion of AF/AFL.

• Country None
• organs None
• Specialty None

A multicenter, randomized double-blind placebo controlled Phase III study of the efficacy of xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastatic colorectal cancer treated with oxaliplatin/5-FU/LV Neuroprotection: Reduction in the risk of occurrence of Grade 3-4 cumulative peripheral sensory neuropathy (PSN) relative to cumulative dose of oxaliplatin.

• Country None
• organs None
• Specialty None

A Randomized Dose Ranging Study of Hexadecasaccharide including Active Control, in Patients with Unstable Angina or Non-ST-segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Coronary Intervention Estudio aleatorizado de búsqueda de dosis de hexadesacárido incluyendo control activo de pacientes con angina inestable o infarto de miocardio sin elevación del segmento ST programados para someterse a intervención coronaria percutánea(SHINE) To evaluate the dose effect of hexadecasaccharide (5 once daily regimens) in patients with unstable angina or non-ST-segment elevation myocardial infarction who are scheduled to undergo percutaneous c...

• Country None
• organs None
• Specialty None

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Fixed- Dose Study Evaluating the Effect of One Dose of Rimonabant (20 mg/day) on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled with Insulin To assess the effect of rimonabant on HbA1c in patients with type 2 diabetes treated with insulin.

• Country None
• organs None
• Specialty None

A Multicenter, Open-Label, Single-Arm Study of Intravenous AVE0005 VEGF Trap Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites Estimate the repeat paracentesis response rate RPRR in advanced ovarian cancer patients with recurrent symptomatic malignant ascites

• Country None
• organs None
• Specialty None

An eight-week, multicenter, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of one fixed 100 mg dose of Saredutant in patients with Major Depressive Disorder To evaluate the efficacy of a 100 mg fixed dose of saredutant compared to placebo in patients with major depressive disorder

• Country None
• organs None
• Specialty None

A multicenter, Randomized, Double Blind, Double Dummy, Parallel Group, Dose Ranging Study of subcutaneous SR123781A with an Enoxaparin calibrator arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement surgery To demonstrate the efficacy of SR123781A in the prevention of Venous Thromboembolism (DVTand/or PE) via demonstration of a dose-response in patients undergoing total hip replacement surgery

• Country None
• organs None
• Specialty None